fluorouracil has been researched along with Mesothelioma in 31 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Mesothelioma: A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The CALGB performed a phase II multicenter study to evaluate the activity of oral capecitabine in patients with malignant mesothelioma (CALGB 39807)." | 9.11 | Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). ( Green, MR; Herndon, JE; Kindler, HL; Otterson, GA; Watson, D, 2004) |
| "Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma of the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of single-agent 5-fluorouracil." | 7.67 | Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. ( Blackshaw, AJ; Harvey, VJ; Ponder, BA; Slevin, ML; Wrigley, PF, 1984) |
| "Mesothelioma is an uncommon malignancy whose global incidence continues to rise." | 5.36 | An epigenetic mechanism for capecitabine resistance in mesothelioma. ( Kosuri, KV; Otterson, GA; Villalona-Calero, MA; Wang, L; Wu, X, 2010) |
| "The CALGB performed a phase II multicenter study to evaluate the activity of oral capecitabine in patients with malignant mesothelioma (CALGB 39807)." | 5.11 | Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). ( Green, MR; Herndon, JE; Kindler, HL; Otterson, GA; Watson, D, 2004) |
| "Raltitrexed ('Tomudex') monotherapy is a conveniently administered alternative to 5-fluorouracil (5-FU) in the first-line treatment of advanced colorectal cancer (CRC), and has single-agent activity in a variety of advanced solid tumours." | 4.81 | Raltitrexed: current clinical status and future directions. ( Cervantes, A; Cunningham, D; Glimelius, B; Maroun, J; Van Cutsem, E, 2002) |
| "We present a case of a 28-year-old female with extensive, bulky malignant peritoneal epitheliod mesothelioma who underwent optimal cytoreduction with peritonectomy followed by intraoperative hyperthermic cisplatin and postoperative intraperitoneal paclitaxel and fluorouracil." | 3.73 | Spontaneous pregnancy following cytoreduction with peritonectomy and hyperthermic intraperitoneal chemotherapy. ( Bidus, MA; Elkas, JC; Kyser, K; Rodriguez, M; Rose, GS, 2006) |
| "Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma of the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of single-agent 5-fluorouracil." | 3.67 | Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. ( Blackshaw, AJ; Harvey, VJ; Ponder, BA; Slevin, ML; Wrigley, PF, 1984) |
| "Malignant pleural mesothelioma is associated with a poor prognosis because of its resistance to treatment." | 2.69 | Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura. ( Astoul, P; Boutin, C; Kasseyet, S, 1999) |
| "Mesothelioma is an uncommon malignancy whose global incidence continues to rise." | 1.36 | An epigenetic mechanism for capecitabine resistance in mesothelioma. ( Kosuri, KV; Otterson, GA; Villalona-Calero, MA; Wang, L; Wu, X, 2010) |
| "Seventeen patients with primary liver cancer were also treated with adriamycin." | 1.26 | Adriamycin in the treatment of cancer. ( Falkson, G; Falkson, HC; van der Merwe, AM; van Dyk, JJ, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (51.61) | 18.7374 |
| 1990's | 2 (6.45) | 18.2507 |
| 2000's | 7 (22.58) | 29.6817 |
| 2010's | 6 (19.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pillai, K | 1 |
| Ehteda, A | 1 |
| Akhter, J | 1 |
| Chua, TC | 1 |
| Morris, DL | 1 |
| Dartigues, P | 1 |
| Stamou, K | 1 |
| Tsamis, D | 1 |
| Pallas, N | 1 |
| Samanta, E | 1 |
| Courcoutsakis, N | 1 |
| Prassopoulos, P | 1 |
| Tentes, AA | 1 |
| Nomura, M | 1 |
| Sasano, H | 1 |
| Okada, Y | 1 |
| Watanabe, T | 1 |
| Sakamoto, S | 1 |
| Sakiyama, Y | 1 |
| Sakamoto, R | 1 |
| Abe, I | 1 |
| Horiuchi, T | 1 |
| Yanase, T | 1 |
| Takayanagi, R | 1 |
| Kosuri, KV | 1 |
| Wu, X | 1 |
| Wang, L | 1 |
| Villalona-Calero, MA | 1 |
| Otterson, GA | 2 |
| Tang, B | 1 |
| Testa, JR | 1 |
| Kruger, WD | 1 |
| Schaub, NP | 1 |
| Alimchandani, M | 1 |
| Quezado, M | 1 |
| Kalina, P | 1 |
| Eberhardt, JS | 1 |
| Hughes, MS | 1 |
| Beresnev, T | 1 |
| Hassan, R | 1 |
| Bartlett, DL | 2 |
| Libutti, SK | 2 |
| Pingpank, JF | 2 |
| Royal, RE | 1 |
| Kammula, US | 1 |
| Pandalai, P | 1 |
| Phan, GQ | 1 |
| Stojadinovic, A | 1 |
| Rudloff, U | 1 |
| Alexander, HR | 2 |
| Avital, I | 1 |
| FALKSON, G | 2 |
| SNYMAN, HJ | 1 |
| LINDEBOOM, GA | 1 |
| Feldman, AL | 1 |
| Beresnev, TH | 1 |
| Mavroukakis, SM | 1 |
| Steinberg, SM | 1 |
| Liewehr, DJ | 1 |
| Kleiner, DE | 1 |
| Herndon, JE | 1 |
| Watson, D | 1 |
| Green, MR | 1 |
| Kindler, HL | 1 |
| Kyser, K | 1 |
| Bidus, MA | 1 |
| Rodriguez, M | 1 |
| Rose, GS | 1 |
| Elkas, JC | 1 |
| Flieger, D | 1 |
| Hainke, S | 1 |
| Fischbach, W | 1 |
| Harvey, VJ | 1 |
| Slevin, ML | 1 |
| Ponder, BA | 1 |
| Blackshaw, AJ | 1 |
| Wrigley, PF | 1 |
| Richter, B | 1 |
| Richter, P | 1 |
| Buchholz, K | 1 |
| Smith, WE | 1 |
| Hubert, DD | 1 |
| Holiat, SM | 1 |
| Sobel, HJ | 1 |
| Davis, S | 1 |
| Nissen, E | 1 |
| Tanneberger, S | 1 |
| Kasseyet, S | 1 |
| Astoul, P | 1 |
| Boutin, C | 1 |
| Omasa, M | 1 |
| Hirata, T | 1 |
| Shoji, T | 1 |
| Bando, T | 1 |
| Hasegawa, S | 1 |
| Inui, K | 1 |
| Wada, H | 1 |
| Van Cutsem, E | 1 |
| Cunningham, D | 1 |
| Maroun, J | 1 |
| Cervantes, A | 1 |
| Glimelius, B | 1 |
| Legha, SS | 1 |
| Muggia, FM | 1 |
| van Dyk, JJ | 1 |
| van der Merwe, AM | 1 |
| Falkson, HC | 1 |
| Kucuksu, N | 1 |
| Thomas, W | 1 |
| Ezdinli, EZ | 1 |
| Umsawasdi, T | 1 |
| Dhingra, HM | 1 |
| Charnsangavej, C | 1 |
| Luna, MA | 1 |
| Gerner, RE | 1 |
| Moore, GE | 1 |
| Umhauer, I | 1 |
| Mannes, P | 1 |
| Derriks, R | 1 |
| Moens, R | 1 |
| Heynen, E | 1 |
| Migueres, J | 1 |
| Jover, A | 1 |
| Levy, A | 1 |
| Vestfrid, MA | 1 |
| Castelleto, L | 1 |
| Giménez, PO | 1 |
| Manzur, R | 1 |
| Oliva Otero, G | 1 |
| Tano Assini, MT | 1 |
| Morere, P | 1 |
| Chauvet, MC | 1 |
| Vaudour, P | 1 |
| Maisse, P | 1 |
| Stain, JP | 1 |
| Lenail, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver[NCT00019786] | Phase 2 | 67 participants (Anticipated) | Interventional | 1999-08-31 | Completed | ||
| Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma[NCT01833832] | Phase 2 | 11 participants (Actual) | Interventional | 2013-04-12 | Completed | ||
| Capecitabine (Xeloda) in Malignant Mesothelioma: A Phase II Study[NCT00004183] | Phase 2 | 27 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Amount of time subject survives without intraperitoneal disease progression after treatment. Disease progression is defined as imageable tumor nodules or increasing ascites persistent on computed tomography (CT) scan as interpreted by the official interpretation of the imaging studies. (NCT01833832)
Timeframe: Amount of time subject survives without intraperitoneal disease progression after treatment, an average of 17 months
| Intervention | Months (Median) |
|---|---|
| Cytoreductive Surgery Followed by HIPEC | 19 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01833832)
Timeframe: Date treatment consent signed to date off study, approximately 34 months and 28 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cytoreductive Surgery Followed by HIPEC | 8 |
Patients who died following the HIPEC procedure. The HIPEC is a surgical procedure in which two large bore catheters are inserted in the abdominal wall over the liver and pelvis. The physician closes the abdominal fascia and the catheters are connected to a perfusion circuit. The temperature of the catheters is carefully monitored while the physician ensures the perfusion is distributed properly by manually moving the abdomen. (NCT01833832)
Timeframe: Patients were assessed every 3 months up to an average of 17 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cytoreductive Surgery Followed by HIPEC | 0 |
Percentage of participants who are alive after treatment. (NCT01833832)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Cytoreductive Surgery Followed by HIPEC | 66.7 |
QOL characteristics were collected using The Functional Assessment of Cancer Therapy-Colorectal Quality of Life (QOL) questionnaire version 4, a validated survey that interrogates physical, emotional, functional, and social well being in cancer related issues on a 5-point scale. Scores range from 0 to 108 points. Higher scores are consistent with a better outcome. (NCT01833832)
Timeframe: Prior to surgery, 6 weeks post surgery, and 3 months post surgery
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Prior to surgery | 6 weeks after surgery | 3 months after surgery | |
| Cytoreductive Surgery Followed by HIPEC | 82.6 | 76.4 | 80.2 |
3 reviews available for fluorouracil and Mesothelioma
| Article | Year |
|---|---|
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2015 |
Raltitrexed: current clinical status and future directions.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 2002 |
Therapeutic approaches in malignant mesothelioma.
Topics: Alkylating Agents; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, | 1977 |
2 trials available for fluorouracil and Mesothelioma
| Article | Year |
|---|---|
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2004 |
Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Cisplatin; Combined Modality | 1999 |
26 other studies available for fluorouracil and Mesothelioma
| Article | Year |
|---|---|
Anticancer effect of bromelain with and without cisplatin or 5-FU on malignant peritoneal mesothelioma cells.
Topics: Antineoplastic Agents; Bromelains; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; D | 2014 |
Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Cytoreduction | 2015 |
Adrenal failure caused by a retroperitoneal malignant mesothelioma.
Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2009 |
An epigenetic mechanism for capecitabine resistance in mesothelioma.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; CpG Islands; Deoxycytidine; DNA Met | 2010 |
Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells.
Topics: Adenosine; Animals; Cell Line; Cell Line, Tumor; Disease Models, Animal; Fibrosarcoma; Fluorouracil; | 2012 |
A novel nomogram for peritoneal mesothelioma predicts survival.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Artificial Intelligence; Ba | 2013 |
EXPERIENCE WITH CHEMOTHERAPY OF CANCER AT THE UNIVERSITY OF PRETORIA.
Topics: Antineoplastic Agents; Aziridines; Breast Neoplasms; Cyclophosphamide; Dactinomycin; Fluorouracil; H | 1964 |
[FRICTION RUB SOUNDS IN THE ABDOMEN].
Topics: Abdomen; Auscultation; Blood Protein Electrophoresis; Cyclophosphamide; Fluorouracil; Friction; Geri | 1964 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regio | 2003 |
Spontaneous pregnancy following cytoreduction with peritonectomy and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fertility; Fluorouracil; H | 2006 |
Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2006 |
Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin.
Topics: Adult; Aged; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Humans; Male; Mesothelioma; Middle | 1984 |
[Malignant mesothelioma of the peritoneum. Case report].
Topics: Adult; Antineoplastic Agents; Cobalt Radioisotopes; Cyclophosphamide; Drug Therapy, Combination; Fem | 1983 |
An experimental model for treatment of mesothelioma.
Topics: Animals; Asbestos; Body Weight; Cricetinae; Cyclophosphamide; Disease Models, Animal; Doxorubicin; F | 1981 |
Influence of pH and serum on the effectivity of antineoplastic agents in vitro.
Topics: Antineoplastic Agents; Cells, Cultured; Culture Media; Fluorouracil; Humans; Hydrogen-Ion Concentrat | 1981 |
A case of repetitive intrapleural cancer chemotherapy using INFUSE-A-PORT for malignant mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Chemotherapy, Cancer, Regiona | 2001 |
Adriamycin in the treatment of cancer.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi | 1976 |
Chemotherapy of malignant diffuse mesothelioma.
Topics: Aged; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; | 1976 |
A case report of malignant pleural mesothelioma with long-term disease control after chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; | 1991 |
Chemotherapy of malignant mesothelioma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Fluorouracil; Glucosamine; Humans; Male; Mesothelioma; M | 1974 |
[Results of polycytostatic therapy in tumorous pleural effusion (author's transl)].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Me | 1974 |
[Antineoplastic polychemotherapy in thoracic pathology].
Topics: Adrenalectomy; Aged; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Cortisone; Cyclop | 1968 |
[3 years of polychemotherapy of pleuro-pulmonary cancer. Apropos of 95 cases].
Topics: Androgens; Antibiotics, Antineoplastic; Antineoplastic Agents; Ascorbic Acid; Azirines; Bronchial Ne | 1968 |
[Diffuse liver necrosis in treatment with 5-fluorouracil].
Topics: Adult; Chemical and Drug Induced Liver Injury; Fluorouracil; Humans; Liver; Male; Mesothelioma; Necr | 1972 |
[Effect of antineoplastic drug therapy in the management of tumor cells of pleural and ascitic effusion].
Topics: Ascites; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Mesothelioma; Mustard Com | 1970 |
[Polychemotherapy of bronchopulmonary cancer].
Topics: Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Cyclophos | 1968 |